- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02598596
Tolerization Reduces Intolerance to Pegloticase and Prolongs the Urate Lowering Effect (TRIPLE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an exploratory open-label, multicenter study to evaluate the effectiveness of a 16-week high zone tolerance regimen of pegloticase on response to therapy (serum uric acid <6 mg/dL) with this drug in adult hyperuricemic patients with gout refractory to conventional therapy.
Eligible subjects will receive 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
Subjects will be monitored for efficacy and safety endpoints through Week 17. Subjects will also have blood drawn for pegloticase levels prior to each dose on Weeks 2, 3, 5, 7, 9, 11, 13,15, and 17. Following Study Week 17, subjects will have an option to continue dosing for an additional 8 weeks.
A subset of subjects will participate in additional pharmacokinetic (PK) assessments.
The study duration, per enrolled patient, will be approximately 26 weeks including a 2-week screening period, a 16-week treatment period (end of treatment [EOT] visit Week 17), and an optional 8-week dosing extension.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birminingham
-
Huntsville, Alabama, United States, 35801
- Rheumatology Associates of North Alabama
-
-
Maryland
-
Wheaton, Maryland, United States, 20902
- The Center for Rheumatology and Bone Research
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01609
- Clinical Pharmacology Study Group
-
-
Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Health System
-
-
Minnesota
-
Eagan, Minnesota, United States, 55121
- Saint Paul Rheumatology
-
-
New York
-
Bronx, New York, United States, 10467
- Montefiore Medical Center
-
Orchard Park, New York, United States, 14127
- Buffalo Rheumatology and Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic
-
-
Pennsylvania
-
Duncansville, Pennsylvania, United States, 16635
- Altoona Center for Clinical Research
-
-
South Carolina
-
Orangeburg, South Carolina, United States, 29118
- Acme Research, Llc
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult (age ≥18 years) men and women of non-childbearing potential, with chronic gout refractory to conventional therapy, defined as patients who have failed to normalize SUA and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose, or for whom these drugs are contraindicated.
- Hyperuricemic - Screening visit SUA must be >6 mg/dL
- On gout flare prophylactic regimen for 7 days prior to the first dose.
- Willing and able to give informed consent and adhere to visit/protocol schedules (informed consent must be given before the first study procedure is performed)
Exclusion Criteria:
- Glucose-6-phosphate dehydrogenase (G6PD) deficiency (confirmed at Screening visit)
- Non-compensated congestive heart failure, uncontrolled arrhythmia, treatment for acute coronary syndrome (ACS) (myocardial infarction or unstable angina) or hospitalization for congestive heart failure within 3 months of screening or uncontrolled blood pressure (>160/100 mm Hg) at baseline (Screening and pre-dose at Week 1 visit )
Women of childbearing potential defined as:
- Pre- or perimenopausal (<24 months of natural [spontaneous] amenorrhea).
- <6 weeks after surgical bilateral oophorectomy with or without hysterectomy.
- Prior treatment with pegloticase or another recombinant uricase
- Prior treatment or concomitant therapy with a polyethylene glycol (PEG) conjugated drug
- Known allergy to PEG products or history of anaphylactic reaction to a recombinant protein or porcine product
- Concurrent treatment with urate lowering agents (ULAs), such as allopurinol and febuxostat. Patients treated with these medications must discontinue treatment 7 days prior to the first dose of study drug
- Recipient of an investigational drug within 4 weeks prior to study drug administration or plans to take an investigational agent during the study
- Current liver disease as determined by alanine transaminase (ALT) or aspartate transaminase (AST) levels >3 times upper limit of normal (ULN)
- History of malignancy within 5 years other than basal cell skin cancer or carcinoma in situ of the cervix
- Has any other medical or psychological condition which, in the opinion of the Investigator, might create undue risk to the patient or interfere with the patient's ability to comply with the protocol requirements, or to complete the study
- Solid organ transplant recipients
- Uncontrolled hyperglycemia with a plasma glucose value >240 mg/dL at screening
Currently on dialysis
Additional Exclusion Criteria for Imaging Sub-study Only
- Contraindication to receiving a gadolinium-based contrast agent (GBCA) or > 2 previous lifetime exposures to a GBCA
- Implanted pacemaker, certain older intracranial aneurysm clips, cochlear implants, certain prosthetic devices, implanted drug infusion pumps, neurostimulators, bone-growth stimulators, certain intrauterine contraceptive devices, or any other type of iron-based metal implants.
Any internal metallic objects such as bullets or shrapnel, as well as most surgical clips, pins, plates, screws, metal sutures, or wire mesh.
Additional Exclusion Criteria for FDG-PET-CT Sub-study Only
Contraindication to FDG
Additional Exclusion Criteria for Pegloticase and AZA Therapy Arm Only
- Any active serious bacterial infection (2 weeks prior to screening) requiring antibiotic treatment
- Severe chronic or recurrent bacterial infections, such as recurrent pneumonia, chronic bronchiectasis
- Current immunocompromised condition, including current or chronic treatment with systemic immunosuppressive agents (e.g., prednisone or equivalent dose >510 mg/day)
- At risk for tuberculosis. Specifically, subjects with: a) current clinical, radiographic, or laboratory evidence of active or latent tuberculosis; b) a history of active tuberculosis within the last 31 years even if it was treated; c) a history of active tuberculosis >31 years ago unless there is documentation that the prior anti-tuberculosis treatment was appropriate in duration and type
- Known history of hepatitis B surface antigen-positivity or hepatitis B DNA positivity
- Known history of hepatitis C RNA-positivity
- Known history of human immunodeficiency virus positivity
- Severe chronic renal impairment (glomerular filtration rate <25 mL/min/1.73 m2)
- AZA treatment is contraindicated or considered inappropriate
- Subject has a homozygous or heterozygous thiopurine methyltransferase (TPMT) variant genotype
- Diagnosis of osteomyelitis
- Known hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome
- Concurrent use of a xanthine oxidase inhibitor
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pegloticase regimen <120 kg - Main Study
Subjects weighing <120 kg will receive a tolerizing dose of pegloticase 8 mg IV weekly for the first 3 weeks of dosing followed by an 8 mg IV dose every 2 weeks for a total of 10 doses.
|
Pegloticase, IV
Other Names:
|
Experimental: Pegloticase regimen ≥120kg
Subjects weighing ≥ 120 kg will be sequentially assigned to 1 of 3 different loading doses (8, 12, and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
|
Pegloticase, IV
Other Names:
|
Experimental: Pegloticase PK Sub-Study
Subjects weighing <120 kg and ≥120 kg will be assigned to 1 of 2 different loading doses (12 and 16 mg) on Study Day 1, and then receive 8 mg on Week 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
Subjects will have multiple blood sampled for PK levels over the 17 week dosing period.
|
Pegloticase, IV
Other Names:
|
Experimental: Pegloticase Imaging Sub-Study
A subset of subjects participating in the Main Study and weighing <120 kg will have dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) performed at Screen and at Week 17.
|
Pegloticase, IV
Other Names:
|
Experimental: Pegloticase FDG-PET-CT Sub-Study
A subset of subjects participating in the Main Study and weighing <120 kg will have fluorodeoxyglucose-positron emission tomography (FDG-PET-CT) to evaluate carotid and aortic (chest) atherosclerosis at Screen and at Week 17.
|
Pegloticase, IV
Other Names:
|
Experimental: Pegloticase and Azathioprine
Subjects weighing <120 kg will receive azathioprine (AZA) daily for a 2-week run-in period, followed by daily AZA plus pegloticase 8 mg IV every 2 weeks through Week 25 for a total of 13 doses.
|
Pegloticase, IV
Other Names:
Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Normalization of serum uric acid (SUA) in subjects receiving a tolerizing regimen of pegloticase
Time Frame: Week 17
|
Determine response rate; the last 3 consecutive levels of SUA must be <6 mg/dL
|
Week 17
|
Normalization of serum uric acid (SUA) in subjects receiving pegloticase and azathioprine (AZA) immunosuppressive therapy
Time Frame: Week 25
|
Determine response rate; the last 3 consecutive levels of SUA must be <6 mg/dL
|
Week 25
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in SUA to end of Treatment
Time Frame: Baseline and Week 17
|
Change from baseline
|
Baseline and Week 17
|
Change from baseline in SUA to end of Treatment
Time Frame: Baseline and Week 25
|
Change from baseline - AZA arm
|
Baseline and Week 25
|
Proportion of subjects with SUA <5 mg/dL
Time Frame: Week 17
|
Proportion of subjects
|
Week 17
|
Proportion of subjects with SUA <5 mg/dL
Time Frame: Week 25
|
Proportion of subjects - AZA arm
|
Week 25
|
Proportion of subjects with SUA <2 mg/dL
Time Frame: Week 17
|
Proportion of subjects
|
Week 17
|
Proportion of subjects with SUA <2 mg/dL
Time Frame: Week 25
|
Proportion of subjects - AZA arm
|
Week 25
|
Infusion reactions (IRs) and anaphylaxis
Time Frame: Week 17
|
Incidence - AZA arm
|
Week 17
|
Infusion reactions (IRs) and anaphylaxis
Time Frame: Week 25
|
Incidence
|
Week 25
|
Incidence of anti-pegloticase antibodies
Time Frame: Week 17
|
Anti-pegloticase antibodies
|
Week 17
|
Incidence of anti-pegloticase antibodies
Time Frame: Week 25
|
Anti-pegloticase antibodies - AZA arm
|
Week 25
|
Mean titer of anti-pegloticase antibodies
Time Frame: Week 17
|
Anti-pegloticase antibodies
|
Week 17
|
Mean titer of anti-pegloticase antibodies
Time Frame: Week 25
|
Anti-pegloticase antibodies AZA arm
|
Week 25
|
Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs
Time Frame: Week 17
|
Incidence
|
Week 17
|
Incidence of gout flares, adverse events (AEs), serious AEs (SAEs), and early terminations due to AEs
Time Frame: Week 25
|
Incidence - AZA arm
|
Week 25
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship in change from baseline in SUA from baseline with rate of infusion reactions
Time Frame: Baseline to Week 17
|
Correlation between change in SUA and infusion reactions
|
Baseline to Week 17
|
Relationship in change from baseline in SUA from baseline with rate of infusion reactions
Time Frame: Baseline to Week 25
|
Correlation between change in SUA and infusion reactions - AZA arm
|
Baseline to Week 25
|
Compare trough pegloticase levels
Time Frame: Week 17
|
Descriptive statistics
|
Week 17
|
Compare trough AZA levels
Time Frame: Week 25
|
Descriptive statistics
|
Week 25
|
Ability of imaging to monitor treatment response
Time Frame: Baseline and Week 17
|
To compare the ability of dual-energy computed tomography (DECT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to monitor treatment response, in a subset of subjects weighing < 120 kg
|
Baseline and Week 17
|
Evaluate change from baseline carotid and aortic (chest) atherosclerosis
Time Frame: Baseline and Week 17
|
Change from baseline as measured by fluorodeoxyglucose-positron emission tomography (FDG-PET-CT), in a subset of subjects weighing < 120 kg
|
Baseline and Week 17
|
Cmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
Tmax of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
AUC of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
Terminal phase half-life of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
CL of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
Vss of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
Accumulation Ratio (AR) of pegloticase in subjects weighing ≥ 120 kg and < 120 kg
Time Frame: Up to Week 17
|
PK parameter
|
Up to Week 17
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AMP-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gout
-
Ai PengRecruitingGout Flare | Intercritical Gout | Advanced Gout | Asymptomatic HyperuricemiaChina
-
AmgenCompletedUncontrolled Gout | Chronic GoutUnited States
-
Sheffield Hallam UniversityCherry Research CommitteeUnknown
-
Olatec Therapeutics LLCRecruitingArthritis | Joint Pain | Gout | Gout Flare | Gouty Arthritis | Acute Gout Flare | Gout AttackUnited States, Spain, France
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalNot yet recruitingAcute Gout | Gout Initiating Urico-lowering TherapyChina
-
GeneScience Pharmaceuticals Co., Ltd.Huashan HospitalRecruitingGout Flare | Acute GoutChina
-
AmgenCompletedGout | Chronic Uncontrolled Gout | Uncontrolled GoutUnited States
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout With Hyperuricemia in Adults
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingPrimary Gout and Hyperuricemia
-
Guangdong Provincial Hospital of Traditional Chinese...RecruitingAcute Pain | Acupuncture | Acute Gout ArthritisChina
Clinical Trials on Pegloticase
-
Savient PharmaceuticalsCompleted
-
Horizon Therapeutics Ireland DACCompletedUncontrolled Gout | Kidney TransplantUnited States
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States
-
Savient PharmaceuticalsCompletedGoutUnited States, Canada, Mexico
-
Horizon Pharma Rheumatology LLCCompletedRefractory Chronic GoutUnited States
-
Savient PharmaceuticalsCompletedChronic Gout Refractory to Conventional TherapyUnited States
-
University of Colorado, DenverRecruitingDiabetes Mellitus, Type 2 | Diabetes | Diabetes Complications | Type 2 Diabetes Mellitus | Diabetic Kidney Disease | Diabetic Nephropathies | Type2 Diabetes | HyperuricemiaUnited States
-
Selecta Biosciences, Inc.Completed
-
John SundySavient PharmaceuticalsCompleted
-
University of Alabama at BirminghamUniversity of MichiganCompleted